C

CSPC Pharmaceutical Group Ltd
HKEX:1093

Watchlist Manager
CSPC Pharmaceutical Group Ltd
HKEX:1093
Watchlist
Price: 6.21 HKD 1.31% Market Closed
Market Cap: 71.7B HKD
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one CSPC Pharmaceutical Group Ltd stock under the Base Case scenario is 6.92 HKD. Compared to the current market price of 6.21 HKD, CSPC Pharmaceutical Group Ltd is Undervalued by 10%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

Relative Value
Base Case
6.92 HKD
Undervaluation 10%
Relative Value
Price
C
Worst Case
Base Case
Best Case

Valuation Multiples

2.3
P/S
P/S
Price to Sales
2.3
vs History
66
vs Industry
55
Median 3Y
2.3
Median 5Y
2.7
Industry
2.4
Forward
2.2
More Details
15.7
P/E
P/E
Price to Earnings
15.7
vs History
25
vs Industry
38
Median 3Y
12.6
Median 5Y
14.4
Industry
20.3
Forward
13.1
More Details
15.8
P/OCF
P/OCF
Price to OCF
15.8
vs History
39
vs Industry
33
Median 3Y
14.9
Median 5Y
14.9
Industry
15.6
More Details
27.2
P/FCFE
P/FCFE
Price to FCFE
27.2
vs History
41
vs Industry
21
Median 3Y
25.6
Median 5Y
23.9
Industry
23.1
More Details
2.1
P/B
P/B
Price to Book Value
2.1
vs History
73
vs Industry
49
Median 3Y
2.2
Median 5Y
3
Industry
2
More Details
2.1
EV/S
EV/S
Enterprise Value to Sales
2.1
vs History
61
vs Industry
64
Median 3Y
1.8
Median 5Y
2.4
Industry
2.5
Forward
1.9
More Details
2.9
EV/GP
EV/GP
Enterprise Value to Gross Profit
2.9
vs History
60
vs Industry
72
Median 3Y
2.5
Median 5Y
3.2
Industry
4.8
More Details
10.1
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
10.1
vs History
38
vs Industry
43
Median 3Y
7.7
Median 5Y
9.6
Industry
12.5
Forward
7.3
More Details
10.1
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
10.1
vs History
50
vs Industry
45
Median 3Y
7.9
Median 5Y
10.1
Industry
15.7
Forward
8.8
More Details
13.9
EV/OCF
EV/OCF
Enterprise Value to OCF
13.9
vs History
30
vs Industry
39
Median 3Y
11.5
Median 5Y
12.1
Industry
14.1
More Details
22.3
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
22.3
vs History
38
vs Industry
26
Median 3Y
20.6
Median 5Y
20.6
Industry
17.6
More Details
1.7
EV/IC
EV/IC
Enterprise Value to IC
1.7
vs History
79
vs Industry
51
Median 3Y
2.2
Median 5Y
3
Industry
1.8
More Details

Multiples Across Competitors

Competitors Multiples
CSPC Pharmaceutical Group Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
CN
CSPC Pharmaceutical Group Ltd
HKEX:1093
72.3B HKD 2.3 15.7 10.1 10.1
US
Eli Lilly and Co
NYSE:LLY
780.6B USD 15.9 70.3 37.7 41.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
375.6B USD 4.2 17.2 12.6 16.5
DK
Novo Nordisk A/S
CSE:NOVO B
2T DKK 7 20 13.2 15
CH
Roche Holding AG
SIX:ROG
216.7B CHF 3.6 26.2 9.8 11.5
CH
Novartis AG
SIX:NOVN
184.6B CHF 4.2 17.4 10.3 13.7
UK
AstraZeneca PLC
LSE:AZN
166.7B GBP 4 28.5 130.9 197.3
US
Merck & Co Inc
NYSE:MRK
210.2B USD 3.3 12.1 8.6 10.4
IE
Endo International PLC
LSE:0Y5F
163.5B USD 70.5 -56 261.3 655.3
FR
Sanofi SA
PAR:SAN
122.8B EUR 1.3 9.7 5.3 6.2
P/E Multiple
Earnings Growth PEG
CN
C
CSPC Pharmaceutical Group Ltd
HKEX:1093
Average P/E: 24.1
15.7
7%
2.2
US
Eli Lilly and Co
NYSE:LLY
70.3
49%
1.4
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
17.2
27%
0.6
DK
Novo Nordisk A/S
CSE:NOVO B
20
18%
1.1
CH
Roche Holding AG
SIX:ROG
26.2
32%
0.8
CH
Novartis AG
SIX:NOVN
17.4
17%
1
UK
AstraZeneca PLC
LSE:AZN
28.5
36%
0.8
US
Merck & Co Inc
NYSE:MRK
12.1
18%
0.7
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -56 N/A N/A
FR
Sanofi SA
PAR:SAN
9.7
28%
0.3
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
CN
C
CSPC Pharmaceutical Group Ltd
HKEX:1093
Average EV/EBITDA: 395.1
10.1
12%
0.8
US
Eli Lilly and Co
NYSE:LLY
37.7
31%
1.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
12.6
8%
1.6
DK
Novo Nordisk A/S
CSE:NOVO B
13.2
14%
0.9
CH
Roche Holding AG
SIX:ROG
9.8
6%
1.6
CH
Novartis AG
SIX:NOVN
10.3
5%
2.1
UK
AstraZeneca PLC
LSE:AZN
130.9
9%
14.5
US
Merck & Co Inc
NYSE:MRK
8.6
9%
1
IE
E
Endo International PLC
LSE:0Y5F
261.3
N/A N/A
FR
Sanofi SA
PAR:SAN
5.3
8%
0.7
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
CN
C
CSPC Pharmaceutical Group Ltd
HKEX:1093
Average EV/EBIT: 1 698.2
10.1
4%
2.5
US
Eli Lilly and Co
NYSE:LLY
41.2
33%
1.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
16.5
13%
1.3
DK
Novo Nordisk A/S
CSE:NOVO B
15
14%
1.1
CH
Roche Holding AG
SIX:ROG
11.5
6%
1.9
CH
Novartis AG
SIX:NOVN
13.7
10%
1.4
UK
AstraZeneca PLC
LSE:AZN
197.3
21%
9.4
US
Merck & Co Inc
NYSE:MRK
10.4
12%
0.9
IE
E
Endo International PLC
LSE:0Y5F
655.3
N/A N/A
FR
Sanofi SA
PAR:SAN
6.2
14%
0.4

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 252,100+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.